Sorrento's MYC Inhibitor Demonstrates Promising Potential For Cancer Treatment
Tony Schwartz, PhD • Wed, Aug. 20
- Scientists have been attempting to target MYC for over a decade in the fight against cancer.
- Sorrento's MYC inhibitor, KJ-Pyr-9, is the first to show efficacy in an animal model of cancer.
- KJ-Pyr-9 could potentially have application in the treatment of almost all human cancers.